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Purpose/Objective: There are a few reports of the radiotherapy for 
synchronous carcinomas in the head and neck (H&N) and esophagus. 
Purpose of this retrospective study is to analyze the results of 
definitive radiotherapy and find the possible prognostic factors. 
Materials and Methods: We reviewed the records of 48 patients with 
synchronous carcinoma in H&N and esophagus who were treated by 
definitive radiotherapy between 2000 and 2012 in our institution. The 
patients with distant metastasis were excluded in this study. 
Regarding head and neck carcinoma, the primary site was 
hypopharynx in 35 patients, larynx in 7, oropharynx in 3 and multiple 
primary sites in 3. Lymph node involvement was seen in 10 patients. 
Eighteen patients were classified to Stage I, 16 to Stage II, 6 to Stage 
III and 8 to Stage IV. Radiation dose in H&N ranged from 34Gy/17fr to 
70Gy/35fr with mean dose of 60Gy/30fr. Concerning esophageal 
carcinoma, single site in esophagus was involved in 23 patients and 
multiple sites in 25 patients. Lymph node metastasis was seen in 21 
patients. Twenty-four patients were classified to Stage I, 9 to Stage II, 
14 to Stage III and 1 to Stage IV. Radiation dose in esophagus ranged 
from 34Gy/17fr to 66Gy/33fr with mean dose of 60Gy/30fr. 
Concurrent 5-FU and cisplatin was administered to 41 patients, and 
the remaining 7 patients were treated by radiation alone. 
Results: The 3-year overall, and cause-specific survival rates were 
38.5% and 52.7% respectively. Advanced esophageal carcinoma stage 
(stage III or IV) had worse 3-year cause-specific survival rate than 
stage I or II esophageal carcinoma (63.8% vs. 24.4%, p=0.02).  
Concerning adverse events, 22 patients (45.8%) needed dmission 
management due to severe acute toxicity. Concurrent chemoradiation 
group had higher rate of admission than radiation alone group (51.2% 
vs. 14.3%). Eighteen patients (37.5%) experienced grade 3 or more 
chronic toxicity (CTCAE ver4.0). Five patients (10.4%) died from 
treatment related complications. 
Conclusions: Definitive concurrent chemoradiotherapy for 
synchronous carcinoma in H&N and esophagus may be a treatment 
option but intensity was so strong that the indication for large field 
radiotherapy and concurrent use of chemotherapy must be very 
cautiously considered. Advanced stage of esophageal carcinoma was 
worse prognostic factor for cause-specific survival rate. 
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Purpose/Objective: To evaluate the dose to carotid artery in patients 
treated with intensity modulated radiation therapy (IMRT) for 
oropharyngeal cancer.  
Materials and Methods: Ten patients with locally or regionally 
advanced oropharyngeal cancer were treated with IMRT. The primary 
tumour involvement was as follows: base of tongue (n=4), tonsil 
(n=2),vallecula (n=3), and soft palate (n=1). The TNM classification of 
the tumour was as follows: T2 (n=1), T3 (n=8), T4a (n=1), N0 (n=5), N1 
(n=2), N2b (n=1), N2c(n=2), and M0 (n=10). The planning CECT scan 
was obtained at 3 mm slice thickness. The right and left common, 
internal, and external carotid arteries were contoured from the level 
of sterno-clavicular joint to the base of skull. The following dose 
schedule was prescribed for IMRT: 70 Gy in 35 fractions (2 Gy per 
fraction) to GTV with 0.5-1.0 cm margin (CTV1), 63 Gy in 35 fractions 
(1.8 Gy per fraction) to high-risk CTV2, and 56 Gy in 35 fractions (1.6 
Gy per fraction) to the low-risk CTV3. A PTV margin of 5 mm was 
given to the respective CTV. The plan was normalized such that at 
least 95% of the volume of PTV1 to be covered by the 70 Gy isodose; 
no more than 20% of PTV1 to receive ≥77 Gy; and no more than 5% of 
PTV1 to receive ≥80.5 Gy. In addition, no more than 1% of any distinct 
PTV to receive ≤ 93% of the prescribed dose and no more than 1% of 
the tissue outside the PTV to receive ≥110% of the dose prescribed to 
PTV1. The treatment was delivered using 6 MV X-rays. Dose-volume 
histogram (DVH) was obtained for each of the 20 carotid arteries. 
Results: The median volume of the carotid artery was 6.2 cc (range, 
4.5-8.7 cc). The median of the mean dose to carotid artery was 58.4 
Gy (range, 53.3-64.3 Gy). The median of the maximum dose to carotid 
artery was 75.9 Gy (range, 61-79.1 Gy). The median and range of V40, 
V50, V60, and V70 were 5.7 cc (4.2-7.9 cc), 5.5 cc (4.1-7.8 cc), 3.8 cc 
(0.9-5.5 cc), and 1.2 cc (0.0-3.0 cc), respectively. With regard to the 
N0 cases, the median of mean and maximum dose to carotid artery 
was 58 Gy and 73.2 Gy respectively. The median of mean and 
maximum dose in N+ cases was 59.9 Gy and 77.3 Gy respectively.  
Conclusions: The dose heterogeneity in IMRT may contribute to 
increase in maximum dose to the carotid arteries. Long term clinical 
outcome may elucidate the risk of cerebrovascular events in patients 
treated with IMRT for oropharyngeal cancer.  
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Purpose/Objective: To compare the differences in resource utilisation 
between Cetuximab plus RT (EBRT) versus Cisplatin plus radiotherapy 
(CRT) taking in to account drug costs, clinical management and the 
costs of managing treatment related toxicity. Effects of treatment on 
quality of life, overall survival and local recurrence were also 
measured .  
Materials and Methods: 20 patients with stage 3 or 4 HNSCC were 
randomised between concomitant weekly Cetuximab or weekly 
Cisplatin plus XRT 70Gy in 35 fractions (10 Cetuximab, 10 Cisplatin). 
All drugs and hospital contacts were recorded to allow assessment of 
the health-economic impact of the management of toxicity additional 
to the initial cost of treatment. Data was collected for the acute 
phase, start of treatment to 6 weeks after completion of radiotherapy 
and late phase, from 6 weeks following completion of treatment to 6 
months following completion of treatment. Quality of life 
questionnaires were completed at baseline, at end of radiotherapy , 6 
weeks following completion of therapy and 6 months following 
completion of treatment. All patients have been followed up for 
greater than 24 months for survival and local recurrence rates. 
Biopsies have been retrospectively tested for p16 positivity by 
immunohistochemisty 
Results: Patients receiving Cisplatin required more intense 
management during the treatment and acute phase they were more 
likely to require overnight admission and required more laboratory 
and radiological investigation compared to those treatment with 
Cetuximab. Patients treated with Cisplatin also had more unplanned 
visits to hospital for management of the side effects of treatment. 
There was no significant difference between the two arm of the study 
for time spent with the head and neck CNS, Dietician or speech and 
language therapist. There were no differences in quality of life 
parameters between the 2 arms of the study although patients 
treatment with Cetuximab were significantly less likely to be using a 
feeding tube at 6 months. c2 p= 0.04. While the study was not 
powered to investigate differences in survival or local recurrence 
rates there was a statistically significant increase in local recurrence 
in patients treated by Cetuximab in this study. log rank p=0.014 
Conclusions: While the overall costs of drug treatment plus 
emergency admission are higher for Cetuximab when compared to 
Cisplatin terms patients undergoing Cisplatin and Radiotherapy 
require significantly more non routine intervention and care than 
patients receiving Cetuximab and Radiotherapy in this randomised 
study and this should be taken in to account when planned further 
trials. A study comparing cisplatin and Cetuximab to investigate 
quality of life and late functional effects of treatment could be viable 
within the NHS. Any future study should also be powered to 
investigate potential differences in overall survival and local 
recurrence rates 
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Purpose/Objective: To report our initial clinical experience of Helical 
Tomotherapy (HT) in the treatment of locally advanced oropharynx 
and inoperable oral cavity carcinoma, in terms of response, acute and 
late toxicity rates. 
Materials and Methods: Between February 2008 and January 2011, 24 
consecutive patients, 15 with oropharyngeal and 9 with oral squamous 
cell carcinoma were treated with exclusive radiotherapy or 
concomitant chemoradiotherapy. Simultaneous integrated boost (SIB) 
in 30 fractions scheme was prescribed to all patients, using Helical 
Tomotherapy. Patients treated with exclusive radiotherapy received a 
dose of 67.5 Gy in 2.25 Gy daily fractions for tumor and 63 Gy in 2.1 
